Sclerostin antibody (SOST) (N-Term)

Details for Product anti-SOST Antibody No. ABIN358751, Supplier: Log in to see
Antigen
  • LOC100313724
  • CDD
  • VBCH
  • 5430411E23Rik
  • sclerostin
  • LOC100313724
  • SOST
  • Sost
Epitope
N-Term
29
17
15
11
9
8
8
7
7
7
2
2
2
2
1
1
1
Reactivity
Human, Mouse (Murine)
116
59
22
3
2
2
2
1
1
1
1
Host
Rabbit
99
18
16
5
1
Clonality
Polyclonal
Conjugate
This Sclerostin antibody is un-conjugated
9
9
7
6
6
6
3
3
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
Application
Enzyme Immunoassay (EIA), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Western Blotting (WB)
112
65
52
13
12
6
6
3
1
1
1
1
Options
Supplier
Log in to see
Supplier Product No.
Log in to see
Immunogen This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from the N-terminal region of human SOST.
Isotype Ig Fraction
Specificity This antibody reacts to SOST.
Purification Protein A column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS
Plasmids, Primers & others Plasmids, Primers & others Sclerostin products on genomics-online (e.g. as negative or positive controls)
Antigen
Alternative Name Sclerostin / SOST (SOST Antibody Abstract)
Background Sclerostin is a secreted glycoprotein with a C-terminal cysteine knot-like (CTCK) domain and sequence similarity to the DAN (differential screening-selected gene aberrative in neuroblastoma) family of bone morphogenetic protein (BMP) antagonists. Loss-of-function mutations in this gene are associated with an autosomal-recessive disorder, sclerosteosis, which causes progressive bone overgrowth. A deletion downstream of this gene, which causes reduced sclerostin expression, is associated with a milder form of the disorder called van Buchem disease.
Gene ID 50964, 9606
UniProt Q9BQB4
Application Notes ELISA: 1/1,000. Western blotting: 1/50 - 1/100. Immunohistochemistry: 1/10 - 1/50.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions For Research Use only
Format Liquid
Concentration 0.25 mg/mL
Buffer PBS with 0.09 % (W/V) sodium azide
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice Avoid repeated freezing and thawing.
Storage 4 °C/-20 °C
Storage Comment Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at-20 °C for longer.
Supplier Images
 image for anti-Sclerostin (SOST) (N-Term) antibody (ABIN358751) anti-Sclerostin (SOST) (N-Term) antibody
 image for anti-Sclerostin (SOST) (N-Term) antibody (ABIN358751) anti-Sclerostin (SOST) (N-Term) antibody (Image 2)
Product cited in: Sato, Cregor, Delgado-Calle, Condon, Allen, Peacock, Plotkin, Bellido: "Protection From Glucocorticoid-Induced Osteoporosis by Anti-Catabolic Signaling in the Absence of Sost/Sclerostin." in: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, Vol. 31, Issue 10, pp. 1791-1802, 2016 (PubMed).

Background publications Semenov, He: "LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST." in: The Journal of biological chemistry, Vol. 281, Issue 50, pp. 38276-84, 2006 (PubMed).

Ellies, Viviano, McCarthy, Rey, Itasaki, Saunders, Krumlauf: "Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity." in: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, Vol. 21, Issue 11, pp. 1738-49, 2006 (PubMed).

Did you look for something else?